Apr. 20 at 4:18 PM
$NVCT The AACR data this week are preclinical, so the bar for a meaningful re-rating is lower — it's more about reinforcing the combination rationale than proving efficacy. The bigger potential catalyst is whenever Phase 1b early efficacy signals emerge (likely H2 2026), which would be the first read on whether NXP900 actually works in biomarker-selected patients. That's the readout that tends to make or break small-cap biotechs like this.
